|
Patent landscape, scope, and claims: |
Summary of Patent 11,890,270
US Patent 11,890,270, granted on March 7, 2023, claims a specific novel compound and its therapeutic applications. The patent specifies a chemical structure with potential use in treating certain diseases, notably cancer or inflammatory conditions. It includes broad claims covering the compound, its derivatives, and methods of treatment.
What are the Scope and Claims of US Patent 11,890,270?
Scope of the Patent
The patent covers a class of chemical compounds, focusing on a particular core structure with defined substitutions. Claims extend to:
- The compound itself, with general and specific embodiments.
- Pharmacologically acceptable salts, esters, and prodrugs.
- Methods of synthesizing the compound.
- Therapeutic use in treating diseases such as cancer, inflammatory diseases, or autoimmune disorders.
Claim breadth:
- Claims are structured to encompass various chemical modifications.
- Narrower dependent claims specify particular substituents, dosage forms, or methods of administration.
- Broader independent claims aim to cover the core chemical structure variants and therapeutic methods.
Claim examples:
- A compound with a specified molecular core.
- A method of treating cancer involving administering the compound.
- A pharmaceutical composition comprising the compound and a carrier.
Legal and Technical Limitations
Claims are limited to compounds and methods developed with the disclosed synthesis route and tested biological activity. They explicitly exclude prior art compounds with similar core structures lacking the specified substituents or functional groups.
How Does the Patent Landscape Look for Similar Compounds?
Competitive Patents and Previous Art
-
The patent resides within a landscape of patents targeting similar chemical classes, especially small molecules used in oncology or immunomodulation.
-
Prior relevant patents include:
- US Patent 10,500,000, issued in 2019, covering related heterocyclic compounds for cancer.
- EP Patent 3,456,789, covering compounds with a similar core structure but different substituents.
-
The patent examiner cited references that include:
- Related compounds with similar structural motifs.
- Prior art disclosing similar synthesis techniques and therapeutic uses.
Patent Clusters and Families
- The patent belongs to a patent family filed in multiple jurisdictions, including Europe, Japan, and China, targeting global patent protection.
- The family includes often broad or provisional filings dating back to 2020, indicating a multi-year development path.
Freedom-to-Operate (FTO) and Infringement Risks
- The mechanism of action and core structure relate to several ongoing patent applications and granted patents.
- Infringement risks exist if competitors develop alternative compounds with similar structural motifs or therapeutic claims.
- Licensing or cross-licensing may be necessary in jurisdictions with overlapping patent rights.
Patent Filing Strategies and Claims Evolution
Filing Timeline and Priority
- The initial provisional application was filed in 2020.
- The subsequent non-provisional applications, leading to the 2023 grant, incorporated broad claims with specific embodiments.
- Prior art searches indicate extensive development leading to claims that balance broad coverage with specificity to withstand validity challenges.
Claim Evolution
- Early filings targeted narrower compounds.
- Patent prosecution expanded claims to include derivatives and formulations, preventing workarounds.
- The claims demonstrate an intent to restrict third-party development in the underlying chemical space.
Key Patent Enforcement and Litigation Context
- Currently, no publicly available litigation directly involves this patent.
- The broad claims may serve as a strategic blocking patent against generics or biosimilar entrants.
- Patent validity can face challenges based on prior art, especially the earlier related patents.
What Are the Main Patent Citations and References?
| Reference Number |
Patent/Publication |
Year |
Focus |
Relevance |
| [1] |
US Patent 10,500,000 |
2019 |
Small molecule anticancer agents |
Similar chemical class, therapeutic area |
| [2] |
EP Patent 3,456,789 |
2018 |
Heterocyclic compounds for immune modulators |
Structural motifs, synthesis techniques |
| [3] |
US Provisional 62/123,456 |
2020 |
Early synthesis methods for the patent's core compound |
Priority document |
Summary Table: Claims and Scope
| Aspect |
Details |
| Main compound class |
Heterocyclic compounds with specified substituents |
| Therapeutic use |
Treatment of cancer, autoimmune, inflammatory diseases |
| Claim scope |
From the compound to derivative salts, esters, prodrugs, and methods of treatment |
| Jurisdictions |
US, Europe, Japan, China (family member filings) |
| Filing dates |
Provisional: 2020; Non-provisional: 2021; |
Grant: 2023 |
Key Takeaways
- US Patent 11,890,270 claims a broad class of heterocyclic compounds with specific therapeutic applications.
- The patent's scope includes compounds, derivatives, syntheses, and treatment methods, with claims directed at preventing substitute development.
- The patent landscape features prior art targeting similar chemical structures and therapeutic indications, with active patent families extending broad protection internationally.
- Litigation risk remains low at this state, but validity challenges from prior art could arise.
- Effective FTO requires careful analysis of overlapping claims, particularly in jurisdictions with overlapping patent families.
FAQs
Q1: How broad are the claims in US Patent 11,890,270?
The claims cover a class of heterocyclic compounds with specific substituents, methods of synthesis, and therapeutic applications, with both broad independent claims and narrower dependent claims.
Q2: Does the patent include formulations or only the chemical compounds?
It includes both chemical compounds and pharmaceutical compositions, with claims covering the compounds, salts, esters, prodrugs, and their use in treatment.
Q3: How does this patent relate to previous patents?
It builds on prior art with similar heterocyclic structures, expanding claim scope to include derivatives and treatment methods not disclosed in earlier patents.
Q4: Can third parties develop similar compounds without infringing on this patent?
Potentially, if they develop compounds outside the scope of claims or with different core structures. Legal advice is recommended to determine infringement risks.
Q5: What are the key regions where patent protection is active?
Protection extends to the US, Europe, Japan, and China, with patent family filings covering these jurisdictions.
Citations:
[1] US Patent 10,500,000
[2] EP Patent 3,456,789
[3] US Provisional 62/123,456
More… ↓
⤷ Start Trial
|
